Grading of breast cancer

• US 7,930,105 B2
• Filed: 11/28/2007
• Issued: 04/19/2011
• Est. Priority Date: 12/21/2001
• Status: Active Grant

• Current Assignee: BioTheranostics, Inc. (Hologic Incorporated), The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: BioTheranostics, Inc. (Hologic Incorporated), The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Ma, Xiao-Jun, Sgroi, Dennis C., Erlander, Mark G.
• Primary Examiner(s): Zeman; Mary K
• Application Number:
  US11/946,835
• Publication Number:
  US 20090092973A1
• Time in Patent Office: 1,238 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57496 involving intracellular compounds

Abstract

Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.

Claims

1. A method to determine the grade of breast cancer cells in a sample from a human subject, said method comprising

assaying said sample for gene expression that is increased in grade III relative to grade I breast cancer, wherein said gene expression is assayed by synthesis of cDNA molecules from expressed RNA of the genes

RACGAP1 (Rac GTPase activating protein 1, chromosomal location 12p13.2-p13.1),

CENPA (centromere protein A (17kD), chromosomal location 2p24-p21),

RRM2 (ribonucleotide reductase M2 polypeptide, chromosomal location 2p25-p24), and

NEK2 (NIMA (never in mitosis gene a)-related kinase, chromosomal location 1q32.2-q41)

in said sample;

and

comparing the expression of the genes, via the cDNA molecules, to the expression of said genes in reference samples of known human grade III breast cancer; and

identifying said sample as containing grade III breast cancer cells.

2. The method of claim 1 wherein said assaying comprises preparing RNA from said sample.

3. The method of claim 2 wherein said RNA is amplified by quantitative PCR.

4. The method of claim 2 wherein said RNA is amplified by reverse transcription PCR (RT-PCR).

5. The method of claim 1 wherein said assaying comprises determining gene expression by an array.

6. The method of claim 1 wherein said sample is a ductal lavage or fine needle aspirate sample.

7. The method of claim 6 wherein said sample is microdissected to isolate one or more cells suspected of being breast cancer cells and said assaying is of RNA in said isolated cells.

15. The method of claim 1, wherein the assaying of said sample further includes synthesis of cDNA molecules from expressed RNA of the gene BUB1 (budding uninhibited by benzimidazoles 1 (yeast homolog), chromosomal location 2q14).

17. The method of claim 15, wherein the cDNAs of said genes are synthesized by quantitative PCR of said RNAs.

18. The method of claim 15, wherein the cDNAs of said genes are synthesized by reverse transcription PCR (RT-PCR).

8. A method to determine the grade of breast cancer cells in a sample from a human subject, said method comprising

assaying said sample for gene expression that is decreased in grade I relative to grade III breast cancer, wherein said gene expression is assayed by synthesis of cDNA molecules from expressed RNA of the genes of

RACGAP1 (Rac GTPase activating protein 1, chromosomal location 12p13.2-p13.1),

CENPA (centromere protein A (17kD), chromosomal location 2p24-p21),

RRM2 (ribonucleotide reductase M2 polypeptide, chromosomal location 2p25-p24), and

NEK2 (NIMA (never in mitosis gene a)-related kinase, chromosomal location 1q32.2-q41)

in said sample;

and

comparing the expression of the genes, via the cDNA molecules, to the expression of said genes in reference samples of known human grade I breast cancer; and

identifying said sample as containing grade I breast cancer cells.

9. The method of claim 8 wherein said assaying comprises preparing RNA from said sample.

10. The method of claim 9 wherein said RNA is amplified by quantitative PCR.

11. The method of claim 9 wherein said RNA is amplified by reverse transcription PCR (RT-PCR).

12. The method of claim 8 wherein said assaying comprises determining gene expression by an array.

13. The method of claim 8 wherein said sample is a ductal lavage or fine needle aspirate sample.

14. The method of claim 13 wherein said sample is microdissected to isolate one or more cells suspected of being breast cancer cells and said assaying is of RNA in said isolated cells.

16. The method of claim 8, wherein the assaying of said sample further includes synthesis of cDNA molecules from expressed RNA of the gene BUB1 (budding uninhibited by benzimidazoles 1 (yeast homolog), chromosomal location 2q14).

19. The method of claim 16, wherein the cDNAs of said genes are synthesized by quantitative PCR of said RNAs.

20. The method of claim 16, wherein the cDNAs of said genes are synthesized by reverse transcription PCR (RT-PCR).